

The Trendlines Group

Shareholder update

Steve Rhodes
Chairman and CEO

Todd Dollinger
Chairman and CEO

Haim Brosh
Chief Financial Officer

October 2020

Agenda

- Corporate highlights
- Covid-19 impact
- Portfolio company highlights

Legal disclaimer

Important notice

This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfolio companies nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever in Singapore, Israel, the United States or in any other jurisdiction. The summary information herein does not purport to be complete. The information in this presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. The information is subject to change without notice.

The past performance of the Company is not necessarily indicative of its future performance. This presentation may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future results, performance or achievements. Actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors and assumptions, such as known and unknown risks and uncertainties, including those risk factors discussed in our Offer Document dated 16 November 2015 and in our other filings with the SGXNET. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those expressed or implied by the forward-looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this presentation only. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

None of the Company or any of its respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

Neither this presentation nor any of its contents may be used without the prior written consent of the Company.

Key corporate developments in 2020

- 9th Exit - sale of ApiFix Ltd.
- Trendlines Agrifood Fund Pte. Ltd. invested in three companies – Equinom Ltd., Insectta Ltd. and Saturas Ltd.
- Establishment of two new medical portfolio companies – Senter Care Ltd. (Israel) and STeP Pte. Ltd. (Singapore)
- 33 portfolio companies raised >US\$38 million.
- Trendlines Labs, our in-house innovation center, expanded into Singapore and China
- Trendlines expands activities in China with the opening of Trendlines Medical Shanghai Innovation Center

Portfolio value expansion



Covid-19 impact

- Work practices in all offices altered to ensure safety and health of all
- Budgets and workplans for portfolio companies revised to extend cash runways and account for current environment
- Travel restrictions, lockdowns, and hospital policies have impacted commercial and clinical trial stage companies
- Maximizing efforts to showcase our portfolio companies to investors and update our shareholders via digital platforms

Our most recent exit – April 2020

Minimally invasive non-fusion surgical system for treating progressive adolescent idiopathic scoliosis

Achievements

- Sales in Canada, Europe, Israel, Asia, U.S.
- Completed >360 successful surgical procedures
- Offices in Israel and U.S.
- Received FDA, CE mark

- Acquired by  OrthoPediatrics®
Leading innovation in Pediatric Orthopedics
- Purchase price: US\$67 million + earnout*
- **Trendlines' return: 37% IRR***
15X ROI*

*as at share price on closing date



The ApiFix minimally invasive scoliosis treatment system

ApiFix




2011 Founded
2020 Exited



Investors Trendlines,
B. Braun



An “inventory” of companies nearing potential exit



*55 portfolio companies as at 30 June 2020;

Numerous near-term portfolio performance targets

	2021	2022	2023/24
AgroScout	Rapid sales growth	Add new markets, new crops	
AquiNovo	Regulatory approval	Launch first product with ADM	Launch 2nd product
Arcuro	Expand US sales		
BioFishency	Rapid sales growth	Launch 2nd product	
FruitSpec	Rapid sales growth	Launch additional applications	
liberDi	Regulatory approval, pivotal clinicals		
miRobot	Advanced field trials	Launch commercial sales	
OrthoSpin	2nd regulatory approval, sales		
PregnanTech	Launch pivotal clinical trial		
Phytolon	Pilots with multiple partners	Scale production capabilities	
Saturas	Rapid sales growth		
ProArc	Launch pivotal clinical trial		
Senter Care	Complete field trials	Partnership agreements; launch	International expansion
Sol Chip	Rapid sales growth		
ViAqua	Regulatory approval, scale production	Launch first product with ADM	Expand new product pipeline

Smart external fixation with real-time feedback

A smart external fixation system that allows real-time physician follow-up and reduces dependency on patient compliance

Achievements

- Successful FIH in US and Israel
- Received FDA clearance
- Two investments from J&J Innovation



The OrthoSpin strut and control box are part of a smart external fixation system



Founded 2014



CEO Oren Cohen
Chair Assaf Dekel, MD



IP 1 National phase
(U.S., EU, China); 1 provisional



Funding US\$7.9 million



Investors
Trendlines,
J&J Innovation



Our Board Members
Todd Dollinger,
Barak Singer




Novel system for meniscus repair


An all-suture, knotless meniscus repair system

Achievements

- Initial sales in the United States
- FDA and CE regulatory approvals
- Distributors in the US; LATAM and APAC countries



- Soft implant
- All-suture
- All-inside
- Knotless



The innovative Arcuro system for meniscus repair



Founded 2013



CEO Lee Ranon



IP U.S. and Chinese patents



Funding ~US\$6.6 million



Investors Strategic and Private investors, surgeons



Our Board Members
Todd Dollinger,
Barak Singer




A natural food color revolution

A broad-spectrum of healthy plant-based colors produced via fermentation technology, using baker's yeast as a biofactory. Phytolon's high-quality and cost-effective pigments offer value for consumers, the environment and food industry

Achievements

- Full POC: color production & food application
- Market focus verified from industry leaders
- Pilots projects at global food industry leaders
- Raised US\$4.6 million, including from strategic investors



Plant-based colors produced via cost-effective and sustainable fermentation of yeast



Founded 2018



CEO Halim Jubran, PhD



IP licensed from Weizmann institute of Science



Funding US\$4.6 million



Investors Millenium, CBG, Trendlines, Mory Arkin,



Our Board Members Maya Schushan Orgad, PhD




Bringing accuracy to fruit yield estimation

Providing accurate, early-season fruit yield estimations using hyperspectral imaging and AI technology.

Achievements

- 2019: Commercial sales in the US and South Africa
- 2020: Commercial sales launch Q1 in Chile
- Applicable for citrus and stone fruits, apples, grapes (table and wine) and avocados
- Proven accuracy rate >90% (average, 97%)



The machine vision technology can estimate from an early stage (green fruit)



FruitSpec.



Founded 2016



CEO Raviv Kula



IP 2 US patents granted, listing process in other territories




Funding Raised US\$5 million in investment rounds



Our Board Members
Sarai Kemp, Steve Rhodes



Looking ahead



Our quality of life depends upon our health and food.

More than ever, our medical and agrifood investments impact lives and provide significant value creation opportunities.



Creating and developing companies **to improve the human condition**

SGX: 42T
OTCQX: TRNLY

+972.72.260.7000
www.trendlines.com



Steve Rhodes, Chairman & CEO

Todd Dollinger, Chairman & CEO

Haim Brosh, Chief Financial Officer

October 2020

GENERAL ANNOUNCEMENT::PRESS RELEASE - SHAREHOLDER UPDATE PRESENTATION

Issuer & Securities

Issuer/ Manager

THE TRENDLINES GROUP LTD.

Securities

THE TRENDLINES GROUP LTD. - IL0011328858 - 42T

Stapled Security

No

Announcement Details

Announcement Title

General Announcement

Date & Time of Broadcast

20-Oct-2020 19:27:27

Status

New

Announcement Sub Title

Press release - Shareholder update presentation

Announcement Reference

SG2010200THRSX33

Submitted By (Co./ Ind. Name)

Haim Brosh